Natural Killer Cells in Older Patients With Acute Myeloid Leukemia
NCT ID: NCT00540956
Last Updated: 2011-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2006-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying natural killer cells in older patients with acute myeloid leukemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilot Study Immunomonitoring Natural Killers Cells in Patients With Myeloid Malignancies Treated With Lenalidomide
NCT02525250
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
NCT07011004
S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia
NCT01338974
Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01185886
Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia
NCT01150058
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Determine the evolution of functional receptors of natural killer (NK) cells after completion of chemotherapy in elderly patients with acute myeloid leukemia in first remission.
Secondary
* Measure the kinetics of cytotoxic functional recovery of NK cells.
* Determine activation markers of NK cells.
OUTLINE: This is a multicenter study.
Patients receive 1 course of consolidation therapy comprising an anthracycline and cytarabine to induce first remission.
Blood is collected on day 0 of the consolidation course and then every 2 weeks for 8 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cytarabine
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of acute myeloid leukemia
* No promyelocytic leukemia
* No prior therapy
PATIENT CHARACTERISTICS:
* Hemoglobin \> 10 g/dL
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Paoli-Calmettes
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Norbert Vey, MD
Role:
Institut Paoli-Calmettes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IPC-LAM-NK
Identifier Type: -
Identifier Source: secondary_id
INCA-RECF0429
Identifier Type: -
Identifier Source: secondary_id
IPC-2006/002
Identifier Type: -
Identifier Source: secondary_id
CDR0000564106
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.